Detection of Latent Tuberculosis Infection in Individuals with Rheumatic Diseases Receiving Immunosuppressive Therapy
Open Access
- 10 September 2026
- journal article
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (4) , 32-39
Abstract
Objective : to identify latent tuberculosis infection (LTBI) in patients with rheumatic diseases receiving immunosuppressive therapy using modern methods of immunodiagnostics. Materials and methods . A combined retrospective-prospective controlled study was conducted. The study group included 79 patients with rheumatic diseases receiving immunosuppressive therapy and having no documented contact with tuberculosis (TB) patients. The control group consisted of 69 healthy individuals with no history of TB contact and no signs of exacerbated chronic diseases. All study participants underwent an interferon-gamma release assay (IGRA) and/or a skin test with a recombinant tuberculosis antigen (RTA). Results : LTBI was detected in 13.9% (11/79) of participants in the study group, which was significantly higher than in the control group (4.4% (3/69); χ²=3.944, p=0.048). During follow-up, positive RTA test results in the study group were observed in 16.1% (9/56) of cases at the second assessment and in 16.7% (6/36) of cases at the third assessment. These rates were higher than at the first (χ²=0.148, p = 0.701) and second assessments (χ²=0.006, p = 0.940), showing no statistically significant differences, although an upward trend was observed.Keywords
This publication has 12 references indexed in Scilit:
- Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in ChinaClinical and Experimental Dermatology, 2025
- Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive reviewAutoimmunity Reviews, 2025
- Systemic vasculitis with latent tuberculosis infection and associated factors: a cross-sectional multicenter studyClinical Rheumatology, 2025
- Evaluation of serial QuantiFERON‐TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti‐IL‐17 treatment (secukinumab and ixekizumab): Real‐world data from a tuberculosis‐endemic countryAustralasian Journal of Dermatology, 2024
- The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapyJournal of Infection and Public Health, 2024
- Latent Tuberculosis Infection and Associated Factors in Patients with Systemic Lupus Erythematosus: a Multicenter, Cross-Sectional StudyMicrobiology Spectrum, 2023
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2022
- Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseasesRMD Open, 2022
- Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologicsExpert Review of Clinical Immunology, 2020
- THE PROGNOSIS OF A POSITIVE TUBERCULIN REACTION IN CHILDHOOD AND ADOLESCENCEAmerican Journal of Epidemiology, 1974